Gaffney, K., Dunkley, L., Goodson, N. et al. (10 more authors) (2017) PMS97 - A Multi-Centre Retrospective Study To Describe The Impact on Healthcare Resource Use And Real World Effectiveness of Golimumab In Ankylosing Spondylitis (AS) In UK Clinical Practice. In: Value in Health. ISPOR 20th Annual European Congress , 04-08 Nov 2017, Glasgow, Scotland. Elsevier , A543-A543.
Abstract
Objectives Study aims were to describe the impact of Tumour Necrosis Factor-α (TNF-α) inhibitor golimumab on UK real-world healthcare resource use (HRU) and evaluate the clinical effectiveness of golimumab in the treatment of Ankylosing Spondylitis (AS). This abstract presents HRU data for the 6 months pre- and post-golimumab initiation as well as effectiveness data at 6 months post-golimumab initiation compared with the closest observation pre-golimumab initiation.
Methods This multicentre observational study of consenting adult patients was carried out via retrospective medical chart review in six UK NHS hospital rheumatology departments between November 2015 and October 2016. Inclusion criteria included AS diagnosis, anti-TNF-α-naïve, received minimum three doses of golimumab for AS, and first dose at least 12 months before data collection. Effectiveness was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Spinal Pain Visual Analogue Scale (VAS) and Bath Ankylosing Spondylitis Functional Index (BASFI). Patients with missing data are excluded from the effectiveness analysis.
Results The study enrolled 47 eligible patients, 74% male, mean age of 46.4 years, mean golimumab treatment duration of 2.3 years. A significant reduction of 30.4% (Mann-Whitney p<0.005) in mean number of rheumatology clinic visits (from 2.3 to 1.6) and a 27.3% reduction in mean number of clinical investigations (from 13.4 to 9.7) over the 12-month period was observed (Mann-Whitney p<0.05). 74% (32/43) of patients achieved a clinically meaningful change (BASDAI score reduced by 2 or more), and overall mean BASDAI score reduced by 3.9 points [n=43] (Mann-Whitney p<0.001). 75% (18/24) of patients achieved a reduction in spinal pain VAS by 2cm or more indicating a treatment response. Overall mean BASFI score improved by 4.1 points [n=26] (Mann-Whitney p<0.001).
Conclusions Golimumab was associated with statistically significant reductions in HRU and clinically meaningful improvements in UK patients with AS during the first 6 months of treatment.
Metadata
Item Type: | Proceedings Paper |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2018 Elsevier. This is an author produced version of a paper subsequently published in Value in Health. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 12 Jan 2018 16:10 |
Last Modified: | 20 Oct 2018 00:39 |
Published Version: | https://doi.org/10.1016/j.jval.2017.08.820 |
Status: | Published |
Publisher: | Elsevier |
Refereed: | Yes |
Identification Number: | 10.1016/j.jval.2017.08.820 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:125912 |